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Abstract
STAT3 mediates signalling downstream of cytokine and growth factor receptors where it
acts as a transcription factor for its target genes, including oncogenes and cell survival regu-
lating genes. STAT3 has been found to be persistently activated in many types of cancers,
primarily through its tyrosine phosphorylation (Y705). Here, we show that constitutive
STAT3 activation protects cells from cytotoxic drug responses of several drug classes. To
find novel and potentially targetable STAT3 regulators we performed a kinase and phospha-
tase siRNA screen with cells expressing either a hyperactive STAT3 mutant or IL6-induced
wild type STAT3. The screen identified cell division cycle 7-related protein kinase (CDC7),
casein kinase 2, alpha 1 (CSNK2), discoidin domain-containing receptor 2 (DDR2), cyclin-
dependent kinase 8 (CDK8), phosphatidylinositol 4-kinase 2-alpha (PI4KII), C-terminal Src
kinase (CSK) and receptor-type tyrosine-protein phosphatase H (PTPRH) as potential
STAT3 regulators. Using small molecule inhibitors targeting these proteins, we confirmed
dose and time dependent inhibition of STAT3-mediated transcription, suggesting that inhibi-
tion of these kinases may provide strategies for dampening STAT3 activity in cancers.
Introduction
STAT3 is constitutively activated in many aggressive cancers where it promotes drug resis-
tance, an inflammatory phenotype and poor clinical outcome [1–3]. Aberrant STAT3 activa-
tion in cancer cells mainly occurs through canonical signalling when activated receptor- or
non-receptor tyrosine kinases phosphorylate STAT3 at the tyrosine (Y) 705 residue. This
results in dimerization of STAT proteins and localization to the nucleus where the STAT
dimers bind to specific binding elements in the DNA and induce transcription of their target
genes [3, 4]. In cancer, sustained STAT3 activation occurs through several mechanisms, such
as cytokine stimulation, mutated cytokine receptors, mutated kinases (such as JAK family
kinases), activation of non-receptor kinases (such as Src family kinases) or loss of negative reg-
ulators (such as SOCS and PIAS proteins) [5]. However, in rare cases such as large granular
lymphocytic leukaemia, aggressive natural killer cell leukaemia and inflammatory
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hepatocellular adenocarcinoma, activating STAT3 mutations have been found in the Src
homology 2 (SH2) domain near the Y705 phosphorylation site that result in a constitutively
activated STAT3 [6–10]. From the mutations in the SH2 domain, STAT3(Y640F) causes
increased hydrophobicity of the STAT dimerization site (pY+3 pocket) that results in more
stable form of STAT3 dimer, constitutive Y705 phosphorylation, enhanced nuclear stability
and increased transcriptional activity [6, 7, 9–11].
Since STAT3 is frequently hyperactivated and is thought to mediate malignancy, it is con-
sidered as potential therapeutic target for several solid and haematological cancers [12–14].
This has sparked multiple efforts to generate inhibitors, primarily aimed at blocking the
SH2-phosphotyrosine dimerization interaction. As a protein-protein interaction, this is a chal-
lenging drug target but at least four small-molecule inhibitors have entered early-phase clinical
testing [TTI-101 (NCT03195699), WP1066 (NCT01904123), OPB-51602 (NCT02058017,
NCT01423903), OPB-31121 (NCT00955812)]. However, most (if not all) reported SH2 bind-
ing STAT3 inhibitors are electrophilic resulting in reactivity with cysteine thiols and they
therefore have low selectivity towards the SH2 domain in more complex biological settings
and often cause off-target toxicities [14–17]. An alternative approach is to inhibit the upstream
signals leading to STAT3 activation, including more readily druggable targets such as kinases
and cell surface receptors for which there are several approved and investigational agents [5].
Targeting the upstream signalling comes with limitations since it requires a specific aberrant
upstream signalling cascade that is known. Furthermore, these approaches do not work well
when there are activating mutations in the STAT3 protein itself [9, 18].
Here we set out to test whether inhibition of other, previously unexplored druggable targets
can achieve inhibition of STAT3 signalling. First, we showed that constitutively active STAT3
protects cells from cytotoxic drug responses of several drug classes including anti-mitotic
inhibitors and inhibitors of apoptosis proteins. Second, using reporter cells expressing either
STAT3 wild type (wt) or constitutively active mutant STAT3(Y640F) in an RNAi screen, we
identified kinases whose knockdown resulted in altered STAT3-activity. Finally, we confirmed
that small molecule inhibition of several of these kinases could block STAT3 activity. Inhibi-
tion of these kinases may therefore be alternative strategies to inhibit STAT3 in cancers and
other pathological conditions.
Materials and methods
Cell lines, virus production and transduction
HEK293 GloResponse SIE Luc2P Hygro cells (Promega) stably expressing a STAT3-dependent
firefly luciferase reporter (here called HEK293sie cells) were grown in DMEM with 10% fetal
bovine serum and 200 μg/ml Hygromycin B (Life Technologies). Cells were maintained at
37˚C with 5% CO2 in a humidified incubator. HEK293sieSTAT3(Y640F) and HEK293sie-
STAT3(wt) cells were generated as previously described [7]. Generation of lentivirus particles
and cell transduction was performed as previously described [18]. All cell lines were grown to
larger volume to make assay ready cells and frozen as aliquots in liquid nitrogen. After thawing
the assay ready cells, they were maintained in culture conditions without antibiotics. All cell
lines were tested negative for mycoplasma using the method described by Choppa et al. (per-
formed by the THL Biobank, Helsinki, Finland) [19, 20].
Drug sensitivity and resistance testing
Drug sensitivity and resistance testing (DSRT) was adapted to screen STAT3(wt) and STAT3
(Y640F) mutant overexpressing HEK293sie cells [21]. The screen consisted of 526 approved
and investigational oncology compounds (S1 File). All compounds were pre-plated at 5
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different concentrations in 10-fold dilutions to black wall clear bottom 384-well plates (Corn-
ing, cat. 3712) using an acoustic dispenser (Echo 550, Labcyte Inc.). 0.1% dimethyl sulfoxide
(DMSO) and 100 μM benzethonium chloride were used as negative and positive controls,
respectively. The list of tested compounds and calculated drug responses can be found in sup-
plementary data 3. The pre-plated drugs were dissolved in 5 μl in cell culture medium with
1:400 CellTox Green (Promega) per well. Subsequently, 20 μl cell suspension (100,000 cells/
ml) per well was dispensed into each well. Cells were incubated for 72 hours, at 37˚C and 5%
CO2. After 72 hours, cell death and viability were measured in multiplexed manner as
described previously [22]. First, CellTox Green (Promega; cytotoxicity readout) was measured
using fluorescence (485/520 nm excitation/emission filter) after which 25 μl CellTiter-Glo
(Promega; viability readout) was dispensed per well, incubated for 10 minutes at room temper-
ature and measured for luminescence. Both toxicity and viability were measured with a PHER-
Astar FS plate reader (BMG Labtech). For the time point experiments, cells were plated in
20 μl/well (100,000 cells/ml) and drugs were added in 5 μl after 0, 48, 64 and 68 hours (for 72,
24, 8, 4-hour perturbation) from cell plating. HEK293sieSTAT3(wt) cells were induced with
IL6 (50 ng/ml) (eBioscience) 3 hours before readout. 72 hours after cell plating, cell viability
and reporter activity were measured with CellTiter-Fluor and ONE-Glo reagents (Promega)
according to the manufacturer’s protocol in multiplexed manner and read with a PHERAstar
FS plate reader (BMG Labtech).
siRNA screens
Chemically synthesized siRNAs from Ambion Silencer1 Select Human siRNA Library V4
(Thermo Fisher Scientific) validated human kinase and phosphatase siRNA library (S2 File)
consisting of 710 kinases and 298 phosphatases were dispensed into 384-well white clear bot-
tom plates (Corning, cat. 3707) in 250 nl using an acoustic dispenser (Echo 550, Labcyte Inc.).
Pre-dispensed plates were foil sealed and stored at -20˚C until use. In the first screen three siR-
NAs targeting one gene were pooled to one well. In all subsequent screens three individual siR-
NAs targeting one gene were in separate wells. Validation siRNAs were obtained from Qiagen
(S3 File). All Ambion siRNA library and Qiagen siRNA screens were performed with the same
protocol. Cells were reverse-transfected with library siRNA (10 nM, for pooled screen 9 nM)
and Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific, cat. 13778150)
using automated transfection as follows: Pre-plated siRNA plates were thawed to room tem-
perature. siRNAs were complexed by addition of 5 μl 1:100 pre- diluted Lipofectamine RNAi-
MAX in OptiMEM (Invitrogen) using a Multidrop Nano dispenser (Thermo Fisher Scientific)
followed by incubation for 20 minutes at room temperature on a plate shaker (400 RPM).
Trypsinized and re-suspended cells were plated in 20 μl yielding 2000 cells/well and 10 nM
siRNA concentration. Assay plates were incubated at 37˚C and 5% CO2, for 72 hours. Wild
type STAT3 cells were induced with IL6 (50 ng/ml) (eBioscience) 3 hours before readout; 2 μl
of diluted IL6 was dispensed using a Multidrop Nano. Subsequently, cell viability and reporter
activity were measured with CellTiter-Fluor and ONE-Glo (Promega) according to the manu-
facturer’s protocol in a multiplexed manner and read with a PHERAstar FS plate reader (BMG
Labtech).
IFNγ activation site (GAS) response element assays
One million HEK293 cells (Promega) were plated on a T25 dish. After 8 h, cells were trans-
fected with 5 μg of a GAS reporter vector (pGL4[luc2P/GAS-RE/Hygro], Promega) and 15 μl
FuGENE HD (Promega, cat no. E2311) according to the manufacturer’s instructions. 16 hours
post-transfection, cells were plated on pre-plated siRNAs as described above. Cells were
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incubated on siRNAs for 48 hours before activation with 100 ng/ml IFNγ (Peprotech) after
which incubation was continued for 24 hours. Subsequently, cell viability and reporter activity
were measured with CellTiter-Fluor and ONE-Glo reagents (Promega), respectively.
Western blotting
300,000 or 250,000 cells were pre-plated on 6-well plates and treated with drugs for 24, 48 or
72 hours. Compounds and their vendors are listed in supplementary file (S3 File). Cells were
lysed in RIPA buffer (Cell Signaling Technology) with 1 mM PMSF. Lysates were briefly soni-
cated (5 × 2 s) to shear the DNA, the amount of protein was determined using a Qubit™ Fluo-
rometer (Life Technologies; Thermo Fisher Scientific), after which 25–50 μg of protein was
loaded per well on 10% SDS-PAGE gels (Bio-Rad). Proteins were run on SDS-PAGE gel for 60
minutes at room temperature (200V) in 1x Tris/Glycine/SDS (cat. 1610772, BioRad) and
transferred to methanol activated (1 minute at room temperature) PVDF membranes (Invitro-
gen) over night at 4˚C (90 mA) in Towbin buffer (25 mM Tris, 192 mM glycine) with 20%
methanol. The membranes were blocked in TBS-Tween (150 mM sodium chloride, 50 mM
TRIS-HCl, pH 7.6 and 0.05% Tween 20) with 5% bovine serum albumin (BSA) for 1 hour at
room temperature. Primary antibodies anti-STAT3 (cat. 2972, Cell Signaling Technology),
anti-pSTAT3 Y705 (cat. ab76315, Abcam), anti-pSTAT3 S727 (cat. 9134, Cell Signaling Tech-
nology) and anti-α-tubulin (cat. T9026, Sigma Aldrich) were diluted 1:1000 in TBS-Tween
+ 5% BSA. Anti-phospho epitope antibodies were probed overnight at 4˚C and total protein
antibodies for 1 hour at room temperature on a rocking plate. Membranes were subsequently
washed with TBS-Tween (3 × 5 min) and probed with LI-COR compatible secondary antibody
at 1:15,000 dilution in TBS-Tween (Odyssey IRdye 800CW and IRdye680) for 1 hour at room
temperature. Membranes were visualized with an Odyssey imaging system (LI-COR Biosci-
ences) and ImageJ version 1.47v was used to quantify band intensities.
Data analysis
DSS, a quantitative drug sensitivity score, which is based on the area under the dose response
curve, was used to measure drug efficacies [21, 23]. The DSS values were calculated in the
Breeze web-based application [24].
Reporter activity of siRNA in primary screens were normalized to cells (negative control,
100%) and siSTAT3 (positive control, 0%) and in validation assay to non-targeting siRNA
(negative control, 100%) and siSTAT3 (positive control, 0%). Viability readouts were normal-
ized to non-targeting siRNA and siDEATH.
Statistical analyses were performed with Prism software version 8.0 (GraphPad Software).
Differences between responses were calculated by using the Student’s t-test (unpaired t-test).
P-values of<0.05 were considered as statistically significant.
Results
STAT3 activation protects cells from cytotoxic drug responses
To test whether STAT3 hyperactivity causes resistance to certain drug classes we used HEK293
cells expressing a firefly luciferase under a STAT3 responsive sis-inducible element (SIE) pro-
moter (HEK293sie cells) and either STAT3(Y640F) mutant or wild type STAT3. Constitutively
active mutant STAT3(Y640F) allowed us to selectively measure the effect of drug responses in
a state of high STAT3 activation. We tested 526 oncology compounds in drug sensitivity and
resistance profiling (DSRT) and measured cell toxicity by a cell-impermeable DNA-binding
dye and viability by a cellular ATP detecting reagent in a multiplexed manner after a 72-hour
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treatment (S1 File). Subsequently, we calculated a drug sensitivity score (DSS) that measures
the area under the dose response curve and represents the efficacy and potency for each com-
pound [21, 23]. When we compared the DSS values of STAT3(wt) and STAT3(Y640F) express-
ing cells we did not see clear differences in the viability readout (Fig 1A). In the cell toxicity
readout, on the other hand, we observed that STAT3(Y640F) is protecting cells from cytotoxic
responses against several drug classes (Fig 1B), such as a selective inhibitor of exportin-1
(XPO1), microtubule targeting agents, Polo like kinase 1 (PLK1), heat shock protein 90
(HSP90) and cyclin-dependent kinase (CDK) inhibitors (Fig 1C and 1D). This suggests that
Fig 1. Constitutive activation of STAT3 protects cells from several drug classes. (A) In an ATP-based cell viability readout (CellTiter-Glo, CTG) chemoprotection
is not perceptible when constitutively active STAT3(Y640F) was compared to STAT3(wt) expressing cells. (B) In a cytotoxicity readout, the constitutively active
STAT3(Y640F) protects cells from cytotoxic effects of several drug classes. (C) Dose-response curves of percent toxicity (CellTox Green, CTX) and percent viability
(D) of HEK293sie cells expressing STAT3(Y640F) or STAT3(wt). Data from one representative experiment out of two independent experiments shown.
https://doi.org/10.1371/journal.pone.0230819.g001
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the constitutively active STAT3 protected cells from the cytotoxic, but not the cytostatic effects
of these drug classes.
siRNA screening reveals kinases and a phosphatase that regulate oncogenic
hyperactive STAT3
To test how hyperactive STAT3 is regulated we designed an siRNA screen using HEK293sie
cells stably co-expressing STAT3(Y640F) or STAT3(wt). The STAT3(Y640F)-expressing cells
exhibited a constitutive STAT3 reporter activity while the activity in the STAT3(wt)-express-
ing cells could be induced by IL6 stimulation. The STAT3(Y640F) expressing HEK293sie cells
had a stronger reporter signal than IL6-induced STAT3(wt) expressing cells (3.6-fold) (S1 Fig).
Using these cells, we performed an siRNA screen where the impact of knockdown of pooled
siRNAs (3 siRNAs per gene) targeting protein/lipid kinase and protein phosphatase genes on
STAT3 transcriptional activity was assessed (Fig 2A, S2 File). STAT3 silencing, which almost
totally abrogated the STAT3-mediated luciferase signal, was used as a positive control (S1 Fig).
In addition, we evaluated the role of JAK1 knockdown in the STAT3(wt) vs. STAT3(Y640F)
expressing cells. While JAK1 knockdown nearly completely blocked IL6-stimulated STAT3
(wt) transcriptional activity, it had only a partial effect on the STAT3(Y640F) signalling (Fig
2B), as has been reported before [9, 18]. From the primary screen consisting of 1,056 genes, we
selected 182 genes, which were retested by assessing the effect of the three individual siRNAs
in separate wells (Fig 2A, S2 File).
From these, we identified 25 hit candidate genes where at least 2 of the 3 individual siRNAs
confirmed. Seven genes validated in a follow-up screen using three additional siRNAs from a
different vendor (Fig 3A and 3B and S2 File). Knockdown of the kinase genes CSNK2, CDC7,
DDR2, CDK8, PI4KII and PTPRH resulted in inhibition of both STAT3(Y640F) and STAT3
(wt) reporter signals (Fig 3A and 3B). Conversely, knockdown of CSK caused a significant
Fig 2. Small interfering RNA (siRNA) screen to identify regulators of hyperactive STAT3. (A) General distribution of the first screen with final validated
hits is highlighted. From each screen, siRNAs reducing cell viability more than 2 times the standard deviation of the negative controls were excluded. In the
validation screen, the siRNAs were obtained from separate source. (B) JAK1 knockdown had a strong effect on STAT3(wt) transcriptional activity, but not in
STAT3(Y640F) expressing cells. Reporter activity was normalized to positive (0%) and negative controls (100%), and cell viability (CellTiter-Fluor).
https://doi.org/10.1371/journal.pone.0230819.g002
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increase of reporter activity in STAT3(Y640F), but not in the IL6-induced STAT3(wt) express-
ing cells, indicating that CSK could be a selective positive regulator of constitutively activated
STAT3 signalling.
Fig 3. Genes regulating STAT3(wt) or STAT3(Y640F) reporter activity. (A-B) Hit genes whose knock-down
resulted in changed transcriptional activity of either STAT3(Y640F) (A) or STAT3(WT) (B). Gene hits were
normalized to siSTAT3 (positive control, 0% transcriptional activity) and non-targeting siRNA (negative control,
100% transcriptional activity). Red and blue lines represent thresholds (2 times standard deviation of control) for
activating and inhibiting hits, respectively. Data comes from one representative experiment out of two independent
experiments with three technical replicates. Bars represent mean ± SD. (C) Six out of seven hits were selective for
STAT3. Only PI4KII knockdown inhibited both STAT3:STAT3 and STAT1:STAT1 transcriptional activity. Data
comes from three independent experiments in triplicates. Two or three siRNAs were used against each gene.
https://doi.org/10.1371/journal.pone.0230819.g003
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To determine whether the gene products of the seven hit genes were selectively regulating
STAT3 signalling, we generated HEK293 cells that transiently expressed a luciferase reporter
for STAT1-driven IFNγ activation site response element (GAS-RE) (Fig 3C). Only knockdown
of PI4KII inhibited both STAT3 and STAT1 transcriptional activity. The rest of the knock-
downs did either not have a significant effect on IFNγ activated STAT1 (CDC7, CSNK2A1,
DDR2, PTPRH) or were non-conclusive (CDK8, CSK).
Small molecule inhibitors of hit kinases regulate STAT3 activity in a dose
and time dependent fashion
To further validate the hit kinases, we tested the effects of STAT3 reporter activity by small
molecule inhibitors targeting the kinase activity of the hit proteins. We used ruxolitinib, silmi-
tasertib, senexin B, BMS863233 and regorafenib to target JAK1/2, CSNK2, CDK8, CDC7 and
DDR2, respectively. All inhibitors induced reduction of STAT3 reporter activity at earlier time
points and lower concentrations than those the cause cytotoxic/cytostatic effects (Fig 4A–4J).
Using these compounds, we also assessed the temporal effects of kinase inhibition. We
observed that the reporter activity inhibition occurred more slowly in STAT3(Y640F) express-
ing cells than the STAT3(wt) cells, suggesting that the STAT3(Y640F) protein de-phosphoryla-
tion is slower. However, this could also be due to the difference in assay settings: in the STAT3
(wt) cells we blocked de novo activation of STAT3(wt) while in the STAT3(Y640F) case the
inhibitors blocked sustained activation. In agreement with the siRNA data, the JAK1/2 inhibi-
tor ruxolitinib did not inhibit mutant STAT3(Y640F) at any time point, whereas inhibition of
IL6-induced STAT3(wt) was seen already after 4 hours (Fig 4A and 4F). The STAT3 reporter
inhibition by the CSNK2 inhibitor silmitasertib was notably slower in the STAT3(Y640F) than
in the STAT3(wt) cells, where a solid reporter inhibition was seen with the STAT3(wt) already
after 4 hours and the corresponding response in the STAT3(Y640F) cells was only seen after
24 hours (Fig 4B and 4G). The CDK8 inhibitor senexin B showed slower reduction of reporter
activity in STAT3(Y640F) than in IL6 induced STAT3(wt) expressing cells (Fig 4C and 4H). A
similar result was seen with another CDK8 inhibitor; senexin A (S2 Fig). The CDC7 inhibitor
BMS863233 led to a slow inhibition of STAT3 activity in both cell lines possibly indicating reg-
ulation at the transcriptional level. Due to the lack of a selective DDR2 inhibitor, we used the
multikinase inhibitor regorafenib, which is known to be a potent DDR2 inhibitor [25]. Regora-
fenib has also been previously proposed to inhibit STAT3 through activation of SHP1 [26].
However, SHP1 (PTPN6) is primarily expressed in hematopoietic cells and we did not detect
significant expression from RNA sequencing of our cells. Regorafenib was only the compound
that clearly showed stronger potency towards STAT3(Y640F) expressing cells at 72 hours. Sim-
ilar to silmitasertib, senexin B and BMS863233, regorafenib treatment resulted in faster
decrease of STAT3 reporter activity in IL6-induced STAT3(wt) expressing cells than in STAT3
(Y640F) cells.
We did not have potent or selective inhibitors against PTPRH, PI4KII and CSK and hence
we could not validate these hits with small molecules. Based on the results from the primary
siRNA screen on STAT3(Y640F) expressing cells, (S3 Fig) we hypothesized that CSK regulates
STAT3 through inhibition of Src family kinases (SFKs) that in turn can phosphorylate and
thus activate STAT3. SFK inhibition could therefore reduce transcriptional activity of STAT3
(wt) and STAT3(Y640F) (S4 Fig). In agreement with this hypothesis, we observed that SFK
inhibitors (saracatinib, CCT196969, dasatinib and A419259) resulted in stronger reporter
activity reduction after 72-hour treatment in STAT3(Y640F) than in wild type STAT3 express-
ing cells, but also affected cell viability in both cell models (S4 Fig). The effect of SFK inhibition
on cell viability was also observed in the siRNA screens and hence, the SFKs had been excluded
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as hits at various stages of the siRNA screening and validation path (Fig 2B, S3 Fig). We
observed that knockdowns of SRC and LCK caused inhibition of transcriptional activity in
STAT3(Y640F) expressing cells, but from these only SRC was highly expressed in HEK293sie-
STAT3(Y640F) cells, suggesting that in our model, CSK may regulate STAT3(Y640F) through
inhibition of SRC (S3 Fig).
Next, we investigated the mechanism of action of the selected kinase inhibitors and tested
the effect of the drugs on STAT3 activity by measuring levels of phosphorylated Y705 STAT3
after compound treatment (Fig 5). We observed that senexin A, senexin B, regorafenib and
BMS863233 caused reduction of pY705 in STAT3(Y640F) cells, but none of the compounds
were able to completely abolish pY705. As expected, JAK1/2 inhibition with 1 μM ruxolitinib
did not markedly reduce pY705 STAT3 level in STAT3(Y640F) expressing cells after 48 or 72
hours (Fig 5), but had a strong inhibitory effect on STAT3(wt) Y705 phosphorylation already
after 4 hours (S5 Fig). We noted that even with as high a concentration as 1 μM, 48 to 72-hour
treatment with the CSNK2 inhibitor silmitasertib did not cause as strong a reduction in pY705
levels of STAT3(Y640F) cells as previously published [27] (Fig 5). However, silmitasertib
reduced S727 phosphorylation in STAT3(Y640F) expressing cells after 48-hour perturbations
(Fig 5). The inhibition of CDK8 and CDC7 caused the strongest reduction of both pY705- and
pS727-STAT3 in STAT3(Y640F) expressing cells whereas in IL6-induced STAT3(wt) express-
ing cells, only the JAK1/2 inhibitor reduced pY705-STAT3 and none of the inhibitors had an
effect on pS727-STAT3. In addition, CDK8 inhibition affected the levels of total STAT3 pro-
tein both in STAT3(wt) and STAT3(Y640F) cells (Fig 5). The hit kinases and the inhibitors
used are summarized in Fig 6.
Fig 4. Dose and time dependency of small molecule inhibitors to STAT3 expression. Kinase inhibitor-mediated
inhibition of STAT3 transcriptional activity is slower in cells expressing STAT3(Y640F) (A-E) than in cells expressing
STAT3(wt) (F-J). STAT3(wt) cells were induced with 50 ng/ml IL6 3 hours prior to the reporter activity readout.
Viability was measured in a multiplexed manner using CellTiter-Fluor. Error bars represent data from at least two
independent experiments with two technical replicates.
https://doi.org/10.1371/journal.pone.0230819.g004
Fig 5. The effect of kinase inhibitors on STAT3 levels in HEK293sieSTAT3(Y640F) or HEK293sieSTAT3(wt)
cells. pY705-, pS727- and total-STAT3 levels in STAT3(Y640F) expressing (A-D) and IL6-induced STAT3(wt) (E-H)
cells after 48-72-hour perturbations with the kinase inhibitors. pY705 and pS747-STAT3 are blotted on individual
membranes and normalized to total-STAT3 from the same membrane. their All the compounds were used at 1 μM
concentration. Mean ± SD. Each dot represents data from an independent experiment. P-values were calculated using
Student’s t-test (unpaired).
https://doi.org/10.1371/journal.pone.0230819.g005
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Discussion
In this study, we sought to identify new druggable approaches to target STAT3 hyperactivity in
cancers. First, to study whether hyperactive STAT3 influences therapeutic responses, we per-
formed drug screening in cells expressing a constitutively active mutant STAT3. We discov-
ered that STAT3 hyperactivity protects cells from undergoing cell death and observed
STAT3-mediated cytoprotection towards multiple antimitotic as well as pro-apoptotic drugs.
This was seen as an effect of reducing apoptotic, but not cytostatic effects. The lack of differ-
ence in cytostatic effects in STAT3(wt) and STAT3(Y640F) cells is in agreement with our pre-
vious report showing that in a strong viability response (with relatively fast-growing cells), it is
often difficult to separate cytotoxic from cytostatic responses [22]. The observed cytostatic
effects are in agreement with previous studies showing that STAT3 can protect cancer cells
from the apoptotic effects of many individual drugs: STAT3 activity controls the expression of
pro-survival genes such as MCL1, BCL2 and BCL2L1 [28, 29]. STAT3 activity can also upregu-
late members of the IAP protein family proteins such as survivin that prevents caspase activity
Fig 6. Schematic illustration of hit kinases/phosphatase and inhibitors targeting the kinases.
https://doi.org/10.1371/journal.pone.0230819.g006
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[30] and extrinsically supress FAS ligand mediated apoptosis [31]. Furthermore, STAT3 can
play a role in regulating multidrug resistance gene expression [32].
We observed STAT3-mediated cytoprotection to several microtubule targeting agents.
STAT3 activity has previously been associated with paclitaxel resistance in ovarian and colo-
rectal cancer cell lines [33, 34]. Docetaxel resistance have been linked to constitutive STAT3
activation and elevated survivin expression in breast cancer [35]. STAT3 and PLK1 are known
to control each other’s transcription in a positive feedback loop resulting in cancer cell sur-
vival, proliferation and resistance to apoptosis [36]. Together this supports the concept that
constitutive STAT3 activity is protecting cancer cells from apoptotic effects of mitotic inhibi-
tion. Cells expressing constitutively active STAT3 were also protected from cytotoxic effects of
the exportin-1 inhibitor selinexor. exportin-1 inhibition with the selinexor analogue KPT-276
has been shown to repress STAT3 activation and survivin transcription in breast cancer cell
lines [37].
Under normal conditions STAT3 signalling can be regulated by several tyrosine kinases
and their upstream/extrinsic regulators (i.e. IL6, IL10, LIF, EGF). Widely known STAT3 acti-
vators include JAK family proteins, receptor tyrosine kinases such as EGFR and MET and
non-receptor tyrosine kinases such as SFKs and Abl [38]. Negative regulators include SOCS
that inhibit STAT3 phosphorylation by blocking the enzymatic activity of JAK or by compet-
ing with STAT3 of binding to the IL6 receptor complex [39, 40], protein tyrosine phosphatases
that dephosphorylate STAT3 (such as PTPRT, PTPRD, SHP2, SHP1 and PTPN9), which
dephosphorylate STAT3 [41], and PIAS proteins that block the DNA binding of STAT3 [42].
We found six kinases (CSK, CSNK2, CDC7, DDR2, CDK8, PI4KII) and a phosphatase
(PTPRH) that indirectly regulate either oncogenic hyperactive STAT3(Y640F) mutant and/or
IL6-induced wild type STAT3 in HEK293sie cells. From these, CSNK2 [27, 43], CDK8 [44]
and CSK [45, 46] have been previously linked to STAT3 signalling. CDC7, DDR2 (also
CD167b), PI4KII and PTPRH, on other hand, have not previously been associated with STAT
activity. The identified kinase/phosphatase regulators were similar between STAT3(Y640F)
and IL6-induced STAT3(wt), with the exception of CSK knockdown that resulted in an
increased activation of STAT3(Y640F) mutant, but did not have a significant effect on IL6-in-
duced STAT3(wt).
SFKs are known to regulate STAT3 phosphorylation independently of JAKs [47–49] and
SFKs are negatively regulated by CSK by phosphorylation of a tyrosine residue at the C-termi-
nal tail site [50]. Our data showed that knockdown of CSK resulted in upregulation of STAT3
(Y640F) transcriptional activity, but did not have a clear effect on IL6-induced wild type
STAT3 activity. This suggests that CSK may selectively regulate active STAT3(Y640F), but not
IL6-induced wild type STAT3. In our cell models, inhibition of SFKs with small-molecule
inhibitors reduced STAT3 reporter activity more efficiently in STAT3(Y640F) than in STAT3
(wt) expressing cells, but these inhibitors also had a strong effect on cell viability. In agreement
with our results, it has been shown that SFK inhibition decreases STAT3(Y640F) activity in
Hep3B cells [9].
CSNK2 knockdown resulted in inhibition of both STAT3(Y640F) and IL6-induced wild
type STAT3 reporter activity in our experiments. The CSNK2 inhibitor 4,5,6,7-tetrabromo-
benzotriazole (TBB) has previously been shown to inhibit both IL6 and Hyper-IL6 induced
STAT3 phosphorylation in Ba/F3 cells [27]. Furthermore, CSNK2 activity was shown to be
required for STAT3(Y640F) activity [27]. However, in our assays CSNK2 inhibition with silmi-
tasertib did not result to strong reduction of pY705 or pS727-STAT3 in either STAT3(Y640F)
or IL6-induced STAT3(wt) cells suggesting that this could be cell line dependent.
CDK8 is a nuclear kinase that is directly involved in transcriptional regulation and is part
of the Mediator complex [51]. We showed that CDK8 knockdown reduces transcriptional
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activity of both hyperactive mutant and IL6-induced wild type STAT3. Nuclear CDK8 has
been shown to regulate STAT3 and STAT1 S727 phosphorylation. It has been suggested that
nuclear CDK8 activity and S727 phosphorylation increases the transcriptional activity of both
STAT3 and STAT1 [44, 52–54]. Bancerek and coworkers showed that CDK8 knockdown
results in reduced levels of STAT3 S727 phosphorylation when induced with IFNβ, but they
did not see changes in STAT3 Y705 phosphorylation [44]. We observed that CDK8 inhibition
with 1 μM senexin A or B results in reduced Y705- and S727-STAT3 phosphorylation in
STAT3(Y640F) cells, but not in IL6-induced STAT3(wt) cells. Furthermore, senexin A and B
reduced total-STAT3 protein in both cell lines.
Our siRNA screen also identified three kinases and one phosphatase (CDC7, PI4KII, DDR2
and PTPRH) that have not previously been linked directly to STAT3. However, another discoi-
din homology domain-consisting RTK, DDR1, which is closely related to DDR2 has been
linked to the regulation of STAT5 [55]. While PTPRH (SAP-1) has not been associated with
STAT activity before, several other tyrosine phosphatases such as PTPN11 (SHP2), PTPRD,
PTPRT (PTPrho) and PTPN6 (SHP1) have previously been found to act as negative regulators
of STAT3 by dephosphorylating active STAT3 [41]. Our results on PTPRH suggest the oppo-
site function, perhaps through removal of STAT3-inhibitory phosphorylations. PTPRH has
been shown to be overexpressed in different adenocarcinomas, including colon, pancreas and
non-small cell lung cancer [56–58].
In conclusion, our data shows that STAT3 hyperactivity protects cells from cytotoxic effects
by several mitotic and pro-apoptotic drugs, arguing that STAT3 inhibition could be used to
enhance the effects of standard chemotherapy. In addition, our data suggests that indirect tar-
geting of STAT3 may be a feasible way to reduce constitutively active STAT3 in cancers instead
of direct STAT3 inhibition. By using cells expressing the constitutively active STAT3(Y640F)
mutant as a tool to study hyperactive STAT3, we show that small molecule inhibitors targeting
CSNK2, CDK8, DDR2 and CDC7 may be used to target hyperactive STAT3 in cancer cells
and warrant further validation of these targets in cancer models with STAT3 hyperactivity.
Supporting information
S1 Fig. Luciferase activities of controls in primary siRNA screen. STAT3(Y640F) and IL6
induced STAT3(wt) expressing cells had 2.6-fold change in mean values of non-targeting
siRNA (siASN) and 3.6-fold change in mean values of only transfection reagent (cells) treated
cells. Bars represent mean and standard deviation of controls on all assay plates in one screen
(total 24 technical replicates per each control). Cells and siSTAT3.7 were used to normalize the
primary screen.
(TIF)
S2 Fig. CDK8 inhibition in STAT3 expressing cells. CDK8 inhibitor senexin A inhibits both
STAT3(Y640F) and STAT3(wt) dose and time dependently. Dots are mean and error bars rep-
resent data from two independent experiments with two technical replicates.
(TIF)
S3 Fig. Src family kinases in STAT3 expressing cells. Effect of CSK and Src family kinases
(SFKs) knockdowns on STAT3 reporter activity and viability of HEK293sieSTAT3(Y640F) (A)
and IL6 induced HEK293sieSTAT3(wt) (B).
(TIF)
S4 Fig. Effect of Src inhibitors on reporter activity of IL6 induced STAT3(wt) and STAT3
(Y640F) expressing cells. Src inhibitors (saracatinib, CCT196969, dasatinib and A419259)
results in stronger reporter activity reduction after 72h in STAT3(Y640F) that in wild type
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STAT3 expressing. Dots are mean and error bars represent data from at least two independent
experiments with two technical replicates.
(TIF)
S5 Fig. Short term perturbation on Y705-phosporylation in IL6 induced STAT3(wt) and
STAT3(Y640F) expressing cells. Four-hour perturbation with JAK1/2 inhibitor ruxolitinib
decreases Y705-phosphorylation of STAT3 in IL6 induced STAT3(wt) expressing cells.
(TIF)
S1 File. Supporting file for Fig 1. Drug sensitivity profiling data for viability (CTG) and toxic-
ity (CTX) readouts, including in house ID, drug name, analysis name, DSS, IC50, drug con-
centration range (min/max conc.), percent inhibition value at each tested concentration
(D1-D5), graph etc. of HEK293sieSTAT3(Y640) and HEK293sieSTAT3(wt) cells.
(XLSX)
S2 File. Supporting file for Figs 2 and 3. Normalized siRNA screening data for each screen
including RefSeq accession number, gene ID, siRNA ID, full gene name gene symbol, percentage
reporter activity normalized to positive (0%) and negative (100%) control and percentage cell via-
bility normalized to positive (0%) and negative (100%) control. Each screen is on separate sheet.
(XLSX)
S3 File. Supporting file for materials and methods. Vendor information of siRNAs and
siRNA screening controls used in Fig 3 and small molecule inhibitors used in Figs 4 and 5 and
S1, S3, S4 Figs.
(XLSX)
S1 Raw images. Raw Western blot scans. Whole membranes of all shown and analyzed West-
ern blot membranes with lane labelling. Lanes with “X” and/or “italics” are not included in the
paper. Blots are supporting Fig 5 and S4 Fig.
(PDF)
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